Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

81. Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education

Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education 29555457 2018 04 20 1555-7162 2018 Mar 16 The American journal of medicine Am. J. Med. Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education. S0002-9343(18)30204-3 10.1016/j.amjmed.2018.02.017 Heart failure education programs are not standardized. The best form of education is unclear. We evaluated (...) whether addition of a novel tablet application to nurse practitioner (NP) education was superior to NP education alone in reducing 30-day readmission after heart failure hospitalization. From February 2015-March 2016, patients admitted to a quaternary academic center with primary diagnosis of heart failure were randomized to 1) treatment - NP education plus tablet application (interactive conditional logic program that flags patient questions to medical staff), or 2) control - NP education

EvidenceUpdates2018

82. Mitral valve interventions in heart failure

Mitral valve interventions in heart failure 29676043 2018 11 14 2055-5822 5 4 2018 08 ESC heart failure ESC Heart Fail Mitral valve interventions in heart failure. 552-561 10.1002/ehf2.12287 Secondary mitral regurgitation (MR) results from left ventricular dilatation and dysfunction. Quantification of secondary MR is challenging because of the underlying myocardial disease. Clinical and echocardiographic evaluation requires a multi-parametric approach. Severe secondary MR occurs in up to one (...) -fourth of patients with heart failure with reduced ejection fraction, which is associated with a mortality rate of 40% to 50% in 3 years. Percutaneous edge-to-edge mitral valve repair (MitraClip) has emerged as an alternative to surgical valve repair to improve symptoms, functional capacity, heart failure hospitalizations, and cardiac haemodynamics. Further new transcatheter strategies addressing MR are evolving. The Carillion, Cardioband, and Mitralign devices were designed to reduce the annulus

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

83. Early identification of acute heart failure at the time of presentation: do natriuretic peptides make the difference?

Early identification of acute heart failure at the time of presentation: do natriuretic peptides make the difference? 29667356 2018 12 17 2018 12 17 2055-5822 5 3 2018 06 ESC heart failure ESC Heart Fail Early identification of acute heart failure at the time of presentation: do natriuretic peptides make the difference? 309-315 10.1002/ehf2.12290 The early identification of patients with acute heart failure (AHF) is challenging as many other diseases lead to a clinical presentation with dyspnea (...) . The aim of the study was to evaluate the impact of natriuretic peptides at common HF study cut-offs on the diagnosis of patients with dyspnea at admission. For this post hoc analysis, we analysed n = 726 European Union (EU) patients from the prospective BACH (Biomarkers in Acute Heart Failure) study. Cut-offs were 350 ng/L (BNP), 300 pmol/L [pro-atrial natriuretic peptide (proANP)], and 1800 ng/L (NT-proBNP). These cut-offs had equivalent 90 days' mortality in the EU cohort of BACH. We analysed

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

84. ASB1 differential methylation in ischaemic cardiomyopathy: relationship with left ventricular performance in end‐stage heart failure patients

ASB1 differential methylation in ischaemic cardiomyopathy: relationship with left ventricular performance in end‐stage heart failure patients 29667349 2018 11 14 2055-5822 5 4 2018 08 ESC heart failure ESC Heart Fail ASB1 differential methylation in ischaemic cardiomyopathy: relationship with left ventricular performance in end-stage heart failure patients. 732-737 10.1002/ehf2.12289 Ischaemic cardiomyopathy (ICM) leads to impaired contraction and ventricular dysfunction, causing high rates (...) ). ASB1 showed a down-regulation in messenger RNA levels (-1.2-fold, P = 0.039). Our findings link a specific ASB1 methylation pattern to LV structure and performance in end-stage ICM, opening new therapeutic opportunities and providing new insights regarding which is the functionally relevant genome in the ischaemic failing myocardium. © 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. Ortega Ana A Cardiocirculatory Unit, Health

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

85. Characteristics and long‐term prognosis of patients with heart failure and mid‐range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta‐analysis

Characteristics and long‐term prognosis of patients with heart failure and mid‐range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta‐analysis 29660263 2018 11 14 2055-5822 5 4 2018 08 ESC heart failure ESC Heart Fail Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. 685-694 10.1002 (...) /ehf2.12283 This study aimed to assess by a meta-analysis the clinical characteristics, all-cause and cardiovascular mortality, and hospitalization of patients with heart failure (HF) with mid-range ejection fraction (HFmrEF) compared with HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Data from 12 eligible observational studies including 109 257 patients were pooled. HFmrEF patients were significantly different and occupied a mid-position between HFrEF

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

86. Homozygous missense MYBPC3 Pro873His mutation associated with increased risk for heart failure development in hypertrophic cardiomyopathy

Homozygous missense MYBPC3 Pro873His mutation associated with increased risk for heart failure development in hypertrophic cardiomyopathy 29663722 2018 11 14 2055-5822 5 4 2018 08 ESC heart failure ESC Heart Fail Homozygous missense MYBPC3 Pro873His mutation associated with increased risk for heart failure development in hypertrophic cardiomyopathy. 716-723 10.1002/ehf2.12288 Hypertrophic cardiomyopathy (HCM) is a primary autosomal-dominant disorder of the myocardium with variable expressivity (...) and penetrance. Occasionally, homozygous sarcomere genetic variants emerge while genotyping HCM patients. In these cases, a more severe HCM phenotype is generally seen. Here, we report a case of HCM that was diagnosed clinically at 39 years of age. Initial symptoms were shortness of breath during exertion. Successively, he developed a wide array of severe clinical manifestations, which progressed to an ominous end-stage heart failure that resulted in heart transplantation. Genotype analysis revealed

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

87. A blood test threshold for diagnosing heart failure in general practice is reviewed

A blood test threshold for diagnosing heart failure in general practice is reviewed NIHR DC | Signal - A blood test threshold for diagnosing heart failure in general practice is reviewed Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal A blood test threshold for diagnosing heart failure in general practice is reviewed Published on 3 May 2017 The cut-off level for the blood test NTproBNP appears to provide the best balance of detecting true cases while excluding false positives (...) when lowered to 125 pg/ml. The trial supported by the NIHR included a sample of people presenting to their GP with suspected heart failure. It aimed to see which method was best for identifying those who needed referral: the blood test alone; clinical decision rules based on clinical symptoms; or the combination of both. The blood test alone at the 125 pg/ml cut-off correctly identified 94% of people with heart failure but led to 50% of people who did not have heart failure being referred

NIHR Dissemination Centre2018

88. Uncertain benefits of BNP blood tests to monitor heart failure treatment

Uncertain benefits of BNP blood tests to monitor heart failure treatment NIHR DC | Signal - Uncertain benefits of BNP blood tests to monitor heart failure treatment Dissemination Centre Discover Portal NIHR DC Discover Uncertain benefits of BNP blood tests to monitor heart failure treatment Published on 6 February 2018 In specialist clinics, using B-type natriuretic peptide (BNP) blood levels to guide treatment in people with chronic heart failure shows promise but did not improve survival (...) for all groups. In this review, the benefit was only seen in patients aged less than 75, who survived an extra 1.5 years on average, and possibly those with poor heart function (reduced ejection fraction). However, there was a reduction in hospital admissions for heart failure for everyone. BNP is a hormone released from the heart muscle, and higher levels may indicate more severe disease. It is currently used for diagnosis, but its use in monitoring treatment has become the subject of recent research

NIHR Dissemination Centre2018

89. The heart failure drug levosimendan doesn’t improve outcomes in adults with severe infections

The heart failure drug levosimendan doesn’t improve outcomes in adults with severe infections NIHR DC | Signal - The heart failure drug levosimendan doesn’t improve outcomes in adults with severe infections Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal The heart failure drug levosimendan doesn’t improve outcomes in adults with severe infections Published on 13 December 2016 Septic shock is a life-threatening condition resulting from serious infection. Adding levosimendan (...) effects on markers of heart function and blood supply in patients with septic shock. Levosimendan is licensed in several countries to treat heart failure, but does not currently have approval from the US Food and Drug Administration. Why was this study needed? There are 150,000 cases of severe sepsis in the UK every year, with 44,000 deaths. Mortality is very high, 30 to 40% even with the best available treatment. Severe infections can lead to septic shock with failure of the heart, kidneys and other

NIHR Dissemination Centre2018

90. Home oxygen therapy prescribed for 15 hours a day did not reduce breathlessness at six months and is hard to take for people with severe chronic heart failure

Home oxygen therapy prescribed for 15 hours a day did not reduce breathlessness at six months and is hard to take for people with severe chronic heart failure NIHR DC | Signal - Home oxygen therapy prescribed for 15 hours a day did not reduce breathlessness at six months and is hard to take for people with severe chronic heart failure Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Home oxygen therapy prescribed for 15 hours a day did not reduce breathlessness at six months (...) and is hard to take for people with severe chronic heart failure Published on 7 January 2016 This NIHR-funded trial found no evidence that long-term home oxygen therapy improves symptoms or quality of life for people with severe chronic heart failure. There were encouraging signs after three months but these were not sustained at six months by which time there was no difference between the oxygen therapy group, who continued to receive best medical care, and the control group. The trial was stopped early

NIHR Dissemination Centre2018

91. Telehealth can help people with heart failure avoid hospital admission

Telehealth can help people with heart failure avoid hospital admission NIHR DC | Signal - Telehealth can help people with heart failure avoid hospital admission Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Telehealth can help people with heart failure avoid hospital admission Published on 18 January 2016 Home telephone or telemonitoring support can bring some aspects of specialised care and monitoring into the homes of people with heart failure. This updated Cochrane review (...) confirmed that people with heart failure who received home telehealth support were less likely to die or go into hospital for problems relating to their heart failure than those getting usual care. Usual care involved visiting a GP surgery or hospital for care and monitoring, which may be difficult for frail people with limited mobility. The review included seventeen new trials since the last review was published five years ago. More evidence is needed on which people would gain most benefit

NIHR Dissemination Centre2018

92. Specialist nurses can manage heart failure drug dosing successfully

Specialist nurses can manage heart failure drug dosing successfully NIHR DC | Signal - Specialist nurses can manage heart failure drug dosing successfully Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Specialist nurses can manage heart failure drug dosing successfully Published on 9 February 2016 Use of specialist nurses to optimise drug dosages using protocols in people with heart failure was more effective than dose monitoring by other health professionals. These nurses (...) had advanced practice certification. This finding came from a review of seven trials with more than 1600 patients. International guidelines recommend two or three first-line medications for people with heart failure. These drugs (beta-adrenergic blocking agents, angiotensin converting enzyme inhibitors and angiotensin receptor blockers) can improve survival and are usually started at low doses by cardiologists and then gradually increased over time, a process managed between cardiologists and GPs

NIHR Dissemination Centre2018

93. “Case management” can prevent people with heart failure being admitted again

“Case management” can prevent people with heart failure being admitted again NIHR DC | Signal - “Case management” can prevent people with heart failure being admitted again Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal “Case management” can prevent people with heart failure being admitted again Published on 30 August 2016 Case management that is initiated in hospital and led by specialist nurses may reduce unplanned hospital readmissions and length of hospital stay (...) for adults with heart failure. Case management is specific, intensive one-to-one care that involves many components to do with planning, coordinating and reviewing the care of people with long-term conditions. This NIHR review of organisational type research found quite a lot of studies: 17 trials and five other studies, including three from the UK. The interventions used by the individual studies in this review varied widely, which highlights some need for caution in interpreting the pooled findings

NIHR Dissemination Centre2018

94. Aldosterone antagonists reduce deaths, including sudden deaths, in people with heart failure

Aldosterone antagonists reduce deaths, including sudden deaths, in people with heart failure NIHR DC | Signal - Aldosterone antagonists reduce deaths, including sudden deaths, in people with heart failure Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Aldosterone antagonists reduce deaths, including sudden deaths, in people with heart failure Published on 17 May 2016 In adults with longstanding heart failure or recent heart attack aldosterone antagonists reduced sudden (...) cardiac deaths and deaths from any cause. There were important side effects, including an increase in kidney injury. Most studies focussed specifically on left heart failure. More research is needed to establish the place of these types of drugs in practice and clinical decision making should be mindful of the impact on effectiveness and side-effects. The findings are in line with current NICE guidance, which include aldosterone antagonists as options in the management of people with this specific

NIHR Dissemination Centre2018

95. A Multivariable Prediction Model for Mortality in Individuals Admitted for Heart Failure

A Multivariable Prediction Model for Mortality in Individuals Admitted for Heart Failure 29509318 2018 03 06 1532-5415 2018 Mar 06 Journal of the American Geriatrics Society J Am Geriatr Soc A Multivariable Prediction Model for Mortality in Individuals Admitted for Heart Failure. 10.1111/jgs.15319 To derive and validate a 30-day mortality clinical prediction rule for heart failure based on admission data and prior healthcare usage. A secondary objective was to determine the discriminatory (...) function for mortality at 1 and 2 years. Observational cohort. Veterans Affairs inpatient medical centers (n=124). The derivation (2010-12; n=36,021) and validation (2013-15; n=30,364) cohorts included randomly selected veterans admitted for HF exacerbation (mean age 71±11; 98% male). The primary outcome was 30-day mortality. Secondary outcomes were 1- and 2-year mortality. Candidate variables were drawn from electronic medical records. Discriminatory function was measured as the area under

EvidenceUpdates2018

96. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study) 29526832 2018 03 12 1524-4539 2018 Mar 11 Circulation Circulation Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). CIRCULATIONAHA.118.034222 10.1161/CIRCULATIONAHA.118.034222 BACKGROUND : Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces (...) the risk of cardiovascular events. We report the effects on heart failure and cardiovascular death overall, in those with and without a baseline history of heart failure, and in other participant subgroups. METHODS : The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) enrolled 10 142 participants with type 2 diabetes mellitus and high cardiovascular risk. Participants were randomly assigned to canagliflozin or placebo and followed for a mean of 188 weeks. The primary end point

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

97. Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes

Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes 29566816 2018 03 23 1558-3597 71 12 2018 Mar 27 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes. 1325-1333 S0735-1097(18)30316-4 10.1016/j.jacc.2018.01.042 Cross correlation analysis (CCA) using tissue Doppler imaging has been shown to be associated with outcome after cardiac resynchronization (...) therapy (CRT) in patients with heart failure (HF) with wide QRS. However, its significance in patients with narrow QRS treated with CRT is unknown. The aim of the current study was to investigate the association of mechanical activation delay by CCA with study outcome in patients with HF enrolled in the EchoCRT trial. Baseline CCA could be performed from tissue Doppler imaging in the apical views in 807 of 809 (99.7%) enrolled patients, and 6-month follow-up could be performed in 610 of 635 (96

EvidenceUpdates2018

98. Opportunistic screening for heart failure with natriuretic peptides in patients with atrial fibrillation: a meta-analysis of individual participant data of four screening studies

Opportunistic screening for heart failure with natriuretic peptides in patients with atrial fibrillation: a meta-analysis of individual participant data of four screening studies 29549089 2018 03 24 1468-201X 2018 Mar 16 Heart (British Cardiac Society) Heart Opportunistic screening for heart failure with natriuretic peptides in patients with atrial fibrillation: a meta-analysis of individual participant data of four screening studies. heartjnl-2017-312781 10.1136/heartjnl-2017-312781 Heart failure (...) (HF) often coexists in atrial fibrillation (AF) but is frequently unrecognised due to overlapping symptomatology. Furthermore, AF can cause elevated natriuretic peptide levels, impairing its diagnostic value for HF detection. We aimed to assess the prevalence of previously unknown HF in community-dwelling patients with AF, and to determine the diagnostic value of the amino-terminal pro B-type natriuretic peptide (NTproBNP) for HF screening in patients with AF. Individual participant data from four

EvidenceUpdates2018

99. Prevalence, clinical correlates, and outcomes of anaemia in multi‐ethnic Asian patients with heart failure with reduced ejection fraction

Prevalence, clinical correlates, and outcomes of anaemia in multi‐ethnic Asian patients with heart failure with reduced ejection fraction 29604185 2018 11 14 2055-5822 5 4 2018 08 ESC heart failure ESC Heart Fail Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fraction. 570-578 10.1002/ehf2.12279 Recent international heart failure (HF) guidelines recognize anaemia as an important comorbidity contributing to poor (...) outcomes in HF, based on data mainly from Western populations. We sought to determine the prevalence, clinical correlates, and prognostic impact of anaemia in patients with HF with reduced ejection fraction across Asia. We prospectively studied 3886 Asian patients (60 ± 13 years, 21% women) with HF (ejection fraction ≤40%) from 11 regions in the Asian Sudden Cardiac Death in Heart Failure study. Anaemia was defined as haemoglobin <13 g/dL (men) and <12 g/dL (women). Ethnic groups included Chinese (33.0

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

100. Management of Chemotherapy-Induced Left Ventricular Dysfunction and Heart Failure in Patients With Cancer While Undergoing Cancer Treatment: The MD Anderson Practice

Management of Chemotherapy-Induced Left Ventricular Dysfunction and Heart Failure in Patients With Cancer While Undergoing Cancer Treatment: The MD Anderson Practice Frontiers | Management of Chemotherapy-Induced Left Ventricular Dysfunction and Heart Failure in Patients With Cancer While Undergoing Cancer Treatment: The MD Anderson Practice | Cardiovascular Medicine Toggle navigation Login using You can login by using one of your existing accounts. We will be provided with an authorization (...) by University of Naples Federico II, Italy Fukushima Medical University, Japan The editor and reviewers' affiliations are the latest provided on their Loop research profiles and may not reflect their situation at the time of review. TABLE OF CONTENTS Supplementary Material total views SHARE ON Perspective ARTICLE Front. Cardiovasc. Med., 28 March 2018 | Management of Chemotherapy-Induced Left Ventricular Dysfunction and Heart Failure in Patients With Cancer While Undergoing Cancer Treatment: The MD Anderson

Frontiers in cardiovascular medicine2018 Full Text: Link to full Text with Trip Pro